Trial Profile

A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BV NSCLC 001 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Aug 2026 Planned primary completion date changed from 9 Dec 2027 to 25 Nov 2026.
10 Nov 2025 Status changed from suspended to active, no longer recruiting.
28 Feb 2025 Status changed from recruiting to suspended due to interim analysis

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com